https://www.selleckchem.com/pr....oducts/debio-0123.ht
mbined with bevacizumab is a potential treatment option, especially for patients with a Karnofsky performance status of ≥70. The International Myeloma Working Group response criteria require two consecutive assessments of paraprotein levels. We conducted an exploratory analysis to evaluate whether a single response assessment could be a substitute for the International Myeloma Working Group criteria using data from JCOG1105, a randomized phase II study on melphalan, prednisolone and bortezomib. Of 91 patients with transplant-ineligib
Curtir
Comentario
Compartilhar
